104 related articles for article (PubMed ID: 28293078)
1. Hepatitis C infected patients need vitamin D3 supplementation in the era of direct acting antivirals treatment.
Kondo Y
World J Gastroenterol; 2017 Feb; 23(8):1325-1327. PubMed ID: 28293078
[TBL] [Abstract][Full Text] [Related]
2. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
[TBL] [Abstract][Full Text] [Related]
3. 1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.
Kondo Y; Kato T; Kimura O; Iwata T; Ninomiya M; Kakazu E; Miura M; Akahane T; Miyazaki Y; Kobayashi T; Ishii M; Kisara N; Sasaki K; Nakayama H; Igarashi T; Obara N; Ueno Y; Morosawa T; Shimosegawa T
PLoS One; 2013; 8(5):e63672. PubMed ID: 23717463
[TBL] [Abstract][Full Text] [Related]
4. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
5. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
6. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
8. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Nagaoki Y; Imamura M; Aikata H; Daijo K; Teraoka Y; Honda F; Nakamura Y; Hatooka M; Morio R; Morio K; Kan H; Fujino H; Kobayashi T; Masaki K; Ono A; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Hayes CN; Miki D; Ochi H; Chayama K
PLoS One; 2017; 12(8):e0182710. PubMed ID: 28797106
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
[TBL] [Abstract][Full Text] [Related]
10. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Sugimoto K; Kim SR; Kim SK; Imoto S; Tohyama M; Kim KI; Ohtani A; Hatae T; Yano Y; Kudo M; Hayashi Y
Oncology; 2015; 89 Suppl 2():42-6. PubMed ID: 26584035
[TBL] [Abstract][Full Text] [Related]
12. Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
Omori-Mizuno Y; Nakayama N; Inao M; Funyu J; Asabe S; Tomita K; Nishikawa K; Hosoda Y; Tanaka M; Hashimoto Y; Yakabi K; Koshima Y; Mochida S
J Gastroenterol Hepatol; 2015 Sep; 30(9):1384-90. PubMed ID: 25778685
[TBL] [Abstract][Full Text] [Related]
13. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D status and viral response to therapy in hepatitis C infected children.
Eltayeb AA; Abdou MA; Abdel-aal AM; Othman MH
World J Gastroenterol; 2015 Jan; 21(4):1284-91. PubMed ID: 25632203
[TBL] [Abstract][Full Text] [Related]
15. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
16. Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.
Lee HW; Chon YE; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Jung KS; Park YN; Han KH
Gut Liver; 2016 May; 10(3):429-36. PubMed ID: 26347515
[TBL] [Abstract][Full Text] [Related]
17. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
18. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
[TBL] [Abstract][Full Text] [Related]
19. [Peg-IFNa-2a/RBV antiviral efficacy in cirrhotic hepatitis C patients after splenectomy or partial splenic embolization].
Xie YM; Li B; Ma L; Pan L; Wei X; Peng XJ; Hao CQ; Zhang Y; Bai XF; Kang WZ; Jia ZS
Zhonghua Gan Zang Bing Za Zhi; 2012 Feb; 20(2):112-5. PubMed ID: 22464782
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
